Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone

Journal of Clinical Microbiology
Michael A PfallerRonald N Jones

Abstract

Delafloxacin, a recently approved anionic fluoroquinolone, was tested within an international resistance surveillance program. The in vitro susceptibilities of 7,914 indicated pathogens causing acute bacterial skin and skin structure infections (ABSSSI) were determined using Clinical and Laboratory Standards Institute (CLSI) broth microdilution MIC testing methods. The U.S. Food and Drug Administration (FDA) susceptibility testing breakpoints and quality control ranges for routine broth microdilution and disk diffusion methods were confirmed. The delafloxacin MIC50/90 (% susceptibility) results were as follows: Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), 0.008/0.25 μg/ml (92.8%); Staphylococcus lugdunensis, 0.016/0.03 μg/ml (99.3%); Streptococcus pyogenes, 0.016/0.03 μg/ml (100.0%); Streptococcus anginosus group, 0.008/0.016 μg/ml (100.0%); Enterococcus faecalis, 0.12/1 μg/ml (66.2%); and Enterobacteriaceae, 0.12/4 μg/ml (69.5%). The FDA clinical breakpoints were used to assess intermethod test agreement between delafloxacin MIC and disk diffusion methods for the indicated pathogens. The intermethod susceptibility test categorical agreement for delafloxacin was acceptable, with only 0.4% very major,...Continue Reading

References

Feb 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Jun 11, 2004·The Journal of Antimicrobial Chemotherapy·Margaret R Hammerschlag, Patricia M Roblin
Jan 19, 2007·Alimentary Pharmacology & Therapeutics·M E FalagasI A Bliziotis
Jul 17, 2007·Clinical Microbiology Reviews·John Turnidge, David L Paterson
Oct 28, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James H Jorgensen, Mary Jane Ferraro
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Mar 11, 2010·AIDS Patient Care and STDs·Hamish MohammedPatricia Kissinger
Oct 12, 2010·The Journal of Antimicrobial Chemotherapy·Matthew S Dryden
Oct 26, 2012·Interdisciplinary Perspectives on Infectious Diseases·Axel Dalhoff
Dec 3, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·William O'RiordanSue Cammarata
Jan 22, 2015·Expert Opinion on Investigational Drugs·Matteo BassettiElda Righi
Mar 31, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R M Humphries, J A Hindler
Oct 20, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edward J SeptimusThomas J Kim

❮ Previous
Next ❯

Citations

Sep 19, 2019·Antimicrobial Agents and Chemotherapy·Richard R WatkinsMichael Z David
Mar 22, 2019·Open Forum Infectious Diseases·Helio S SaderRonald N Jones
Oct 4, 2020·Journal of Veterinary Pharmacology and Therapeutics·Patrick F McDermott, James J Davis

❮ Previous
Next ❯

Software Mentioned

RangeFinder

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.